These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21352072)

  • 1. Emerging drugs for Guillain-Barré syndrome.
    Walgaard C; Jacobs BC; van Doorn PA
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):105-20. PubMed ID: 21352072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IVIG treatment and prognosis in Guillain-Barré syndrome.
    van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome].
    Orlikowski D; Quijano-Roy S; Sivadon-Tardy V; Raphael JC; Gaillard JL
    Arch Pediatr; 2006 Dec; 13(12):1561-5. PubMed ID: 17030119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
    van Doorn PA; Ruts L; Jacobs BC
    Lancet Neurol; 2008 Oct; 7(10):939-50. PubMed ID: 18848313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatments and outcome predictors in Guillain-Barré syndrome].
    Uchibori A; Chiba A
    Nihon Rinsho; 2013 May; 71(5):845-9. PubMed ID: 23777092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatment landscape for Guillain-Barré Syndrome (GBS): what's new?
    Sprenger-Svačina A; Svačina MKR; Gao T; Zhang G; Sheikh KA
    Expert Opin Investig Drugs; 2024 Sep; 33(9):881-886. PubMed ID: 38980318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome.
    Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC
    Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial.
    Korinthenberg R; Schessl J; Kirschner J; Mönting JS
    Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
    Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
    J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The rational immunotherapy with intravenous immunoglobulin in neurologic diseases].
    Korsak J
    Pol Merkur Lekarski; 2011 Jun; 30(180):430-4. PubMed ID: 21751554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
    Misawa S
    Brain Nerve; 2015 Nov; 67(11):1421-8. PubMed ID: 26560957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
    Dididze MN
    Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
    Prado MB; Adiao KJB; Turalde CWR; Dasig DA
    Acta Neurol Belg; 2024 Aug; 124(4):1237-1250. PubMed ID: 38553651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study.
    El-Bayoumi MA; El-Refaey AM; Abdelkader AM; El-Assmy MM; Alwakeel AA; El-Tahan HM
    Crit Care; 2011 Jul; 15(4):R164. PubMed ID: 21745374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.